Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Ermenegildo Zegna N.V. Ordinary Shares (ZGN) Price & Performance

Kymera Therapeutics Inc. Common StockTrade
Ermenegildo Zegna N.V. Ordinary SharesTrade

Price performance (Past 24H)

Key statistics

Kymera Therapeutics Inc. Common Stock vs Ermenegildo Zegna N.V. Ordinary Shares — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Ermenegildo Zegna N.V. Ordinary Shares trades at $12.8 (market cap $3.48B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 2.5× Ermenegildo Zegna N.V. Ordinary Shares's market cap, and Ermenegildo Zegna N.V. Ordinary Shares pays a 1.06% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Ermenegildo Zegna N.V. Ordinary Shares for 0 Days on average.

KYMRZGN
Market Cap
$8.87B$3.48B
Volume
779,1071,076,161
Sector
HealthConsumer Cyclical
52-Week High
$127.31$15.25
52-Week Low
$55.80$8.69
Typical Hold Time
0 Days0 Days
Enterprise Value
$8.26B$4.43B
Dividend Yield
—1.06%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kymera Therapeutics Inc. Common Stock

No Aura AI signal available yet.

Ermenegildo Zegna N.V. Ordinary Shares

ZGN trades at $12.94, up 2.7% with a neutral technical outlook. The stock shows mixed fundamentals with a high P/E of 38.5 but strong gross margins of 67.58%. Recent earnings beat expectations in three of the last four quarters, though Q2 2026 missed estimates. Analyst consensus is bullish with a $14.12 price target and 66.7% buy ratings. Revenue growth continues with 2025 reaching $1.92B, though net margins compressed to 3.98%.

ZGN presents a growth opportunity with expanding DTC momentum and margin potential, but faces valuation concerns and competitive pressures. The stock's upside depends on sustained earnings growth and successful execution of the retail-first strategy amidst fashion sector volatility.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KYMR
100% Buy0% Sell
Avg holding period · 0 Days
ZGN
100% Buy0% Sell
Avg holding period · 0 Days

About Kymera Therapeutics Inc. Common Stock

Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.

Read more on KYMR →

About Ermenegildo Zegna N.V. Ordinary Shares

Ermenegildo Zegna N.V. is a luxury fashion group whose brands include Zegna, Thom Browne, and Tom Ford Fashion. The company operates a vertically integrated supply chain, sourcing wool from its own Australian farm through to finished garment production.

Read more on ZGN →